No. BioMarin Pharmaceutical Inc. (BMRN) does not pass our halal screen, as of 18 November 2026. It fails on interest-bearing debt.
NASDAQ · Healthcare · Screened 18 November 2026. Its verdict has changed 9 times since 24 September 2026, most recently on 2026-11-04 (broke).
| Business activity | Pass | From the 10-K (2025): The company's entire revenue of $3.22 billion is derived from the sale of pharmaceutical products for rare diseases and related royalties, all of which are permissible. |
| Interest-bearing debt | Fail | Total debt is 37.1% of market cap (limit 30%). |
| Cash & interest-bearing securities | Pass | Cash & securities are 7.7% of market cap (limit 30%). |
| Non-permissible income (< 5%) | Pass | Interest income is 2.1% of revenue (limit 5%). The annual report shows no other non-permissible revenue. |
See every change across all stocks on the public verdict ledger.
No. BioMarin Pharmaceutical Inc. (BMRN) does not pass our halal screen, as of 18 November 2026. It fails on interest-bearing debt.
Two of the tests compare debt and cash with the company's market value. When the share price moves, those ratios move, so a stock can cross the 30% line without the business changing at all. Its verdict has changed 9 times since 24 September 2026, most recently on 2026-11-04 (broke).
We use an AAOIFI-style screen: the business itself must be permissible, interest-bearing debt and interest-bearing cash must each be under 30% of market value, and non-permissible income must be under 5% of revenue. It is an automated estimate, not a fatwa.
Free halal check for US, Australian, Malaysian and Singapore stocks.
Check a stockAAOIFI-style screen by Barakah Profits. Automated estimate, not a fatwa. Always confirm with a qualified scholar before investing. Financial data provided by Twelve Data. This is general information, not financial advice.